William Blair Predicts CVRx’s FY2024 Earnings (NASDAQ:CVRX)

CVRx, Inc. (NASDAQ:CVRX) – Equities research analysts at William Blair lifted their FY2024 earnings estimates for CVRx in a research note issued on Tuesday, January 14th. William Blair analyst M. Andrew now forecasts that the company will earn ($2.62) per share for the year, up from their previous forecast of ($2.65). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for CVRx’s current full-year earnings is ($2.62) per share. William Blair also issued estimates for CVRx’s Q4 2024 earnings at ($0.35) EPS, Q1 2025 earnings at ($0.64) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($2.08) EPS, Q1 2026 earnings at ($0.55) EPS, Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.82) EPS.

Several other research firms also recently issued reports on CVRX. Craig Hallum upped their price objective on CVRx from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, November 4th. Lake Street Capital lifted their price target on shares of CVRx from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Cantor Fitzgerald restated an “overweight” rating and issued a $14.00 price objective on shares of CVRx in a report on Wednesday, October 23rd. Canaccord Genuity Group upped their price target on CVRx from $17.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $16.00 target price (up from $13.00) on shares of CVRx in a report on Wednesday, October 30th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $16.67.

CVRx Trading Up 5.3 %

CVRX opened at $17.00 on Thursday. The company has a market cap of $412.49 million, a P/E ratio of -6.30 and a beta of 1.26. The company has a current ratio of 11.32, a quick ratio of 10.23 and a debt-to-equity ratio of 0.76. The company’s 50 day moving average is $14.01 and its 200-day moving average is $11.00. CVRx has a 1-year low of $6.40 and a 1-year high of $29.23.

CVRx (NASDAQ:CVRX) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.12). CVRx had a negative net margin of 123.75% and a negative return on equity of 89.06%. The company had revenue of $13.37 million during the quarter, compared to analyst estimates of $13.28 million. During the same period in the prior year, the firm earned ($0.43) earnings per share.

Institutional Trading of CVRx

Hedge funds and other institutional investors have recently modified their holdings of the business. Parkman Healthcare Partners LLC increased its holdings in shares of CVRx by 52.6% in the third quarter. Parkman Healthcare Partners LLC now owns 682,897 shares of the company’s stock worth $6,016,000 after purchasing an additional 235,277 shares during the period. Geode Capital Management LLC grew its holdings in shares of CVRx by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 295,124 shares of the company’s stock valued at $2,600,000 after purchasing an additional 6,443 shares during the last quarter. State Street Corp lifted its stake in shares of CVRx by 11.4% in the 3rd quarter. State Street Corp now owns 264,733 shares of the company’s stock valued at $2,332,000 after acquiring an additional 27,071 shares during the last quarter. Squarepoint Ops LLC grew its holdings in shares of CVRx by 26.3% in the second quarter. Squarepoint Ops LLC now owns 91,999 shares of the company’s stock worth $1,103,000 after purchasing an additional 19,165 shares during the last quarter. Finally, PDT Partners LLC purchased a new position in shares of CVRx in the third quarter valued at about $543,000. Institutional investors own 75.27% of the company’s stock.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.